MX2013011985A - Nanosuspensiones de farmacos secadas por congelamiento. - Google Patents

Nanosuspensiones de farmacos secadas por congelamiento.

Info

Publication number
MX2013011985A
MX2013011985A MX2013011985A MX2013011985A MX2013011985A MX 2013011985 A MX2013011985 A MX 2013011985A MX 2013011985 A MX2013011985 A MX 2013011985A MX 2013011985 A MX2013011985 A MX 2013011985A MX 2013011985 A MX2013011985 A MX 2013011985A
Authority
MX
Mexico
Prior art keywords
freeze dried
dried drug
freeze
drug nanosuspensions
dried
Prior art date
Application number
MX2013011985A
Other languages
English (en)
Other versions
MX362344B (es
Inventor
Sabine Karine Katrien Inghelbrecht
Henning Gieseler
Jakob Andreas Beirowski
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2013011985A publication Critical patent/MX2013011985A/es
Publication of MX362344B publication Critical patent/MX362344B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con una nanosuspensión de fármaco secada por congelamiento (también conocida como liofilización); la presente composición de nanosuspensión de fármaco secada por congelamiento tiene una estabilidad aceptable de la distribución de tamaños de partículas durante su almacenamiento, incluso en el almacenamiento a largo plazo.
MX2013011985A 2011-04-15 2012-04-13 Nanosuspensiones de farmacos secadas por congelamiento. MX362344B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161475811P 2011-04-15 2011-04-15
PCT/EP2012/056818 WO2012140220A1 (en) 2011-04-15 2012-04-13 Freeze dried drug nanosuspensions

Publications (2)

Publication Number Publication Date
MX2013011985A true MX2013011985A (es) 2013-11-04
MX362344B MX362344B (es) 2019-01-11

Family

ID=45937395

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011985A MX362344B (es) 2011-04-15 2012-04-13 Nanosuspensiones de farmacos secadas por congelamiento.

Country Status (21)

Country Link
US (5) US20140038996A1 (es)
EP (2) EP3799860A1 (es)
JP (1) JP6161593B2 (es)
CN (2) CN108210469A (es)
AU (1) AU2012241726C1 (es)
BR (1) BR112013026363B1 (es)
CA (1) CA2832410C (es)
CY (1) CY1123434T1 (es)
DK (1) DK2696848T3 (es)
ES (1) ES2823805T3 (es)
HK (1) HK1257447A1 (es)
HR (1) HRP20201241T1 (es)
HU (1) HUE050970T2 (es)
LT (1) LT2696848T (es)
MX (1) MX362344B (es)
PL (1) PL2696848T3 (es)
PT (1) PT2696848T (es)
RS (1) RS60651B1 (es)
RU (1) RU2643062C2 (es)
SI (1) SI2696848T1 (es)
WO (1) WO2012140220A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2701720T3 (pl) 2011-04-28 2017-12-29 Oncopeptides Ab Liofilizowany preparat cytotoksycznych dipeptydów
SI2928463T1 (sl) 2012-10-26 2020-03-31 Oncopeptides Ab Liofilizirani pripravki melfalan flufenamida
US20150246060A1 (en) 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
EP2969227B1 (en) * 2013-03-15 2019-05-08 Iceutica Inc. Abiraterone acetate formulation
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
HUP1500055A1 (hu) * 2015-02-09 2016-08-29 Druggability Technologies Ip Holdco Ltd Abirateron acetát komplexei, eljárás elõállításukra, és az azokat tartalmazó gyógyászati készítmények
CN105902496B (zh) * 2016-04-18 2019-10-25 沈阳药科大学 一种纳米混悬液固体化过程的处理方法
US10507165B2 (en) * 2017-05-31 2019-12-17 Adienne Pharma & Biotech Sa Multi chamber flexible bag and methods of using same
RU2665383C9 (ru) * 2017-06-22 2019-07-23 Общество с ограниченной ответственностью "Вириом" Фармацевтическая наносуспензия для терапии ВИЧ-инфекции
WO2019012100A1 (en) 2017-07-14 2019-01-17 Janssen Pharmaceutica Nv EXTENDED ACTION FORMULATIONS
RU2721562C1 (ru) * 2019-06-04 2020-05-20 Автономная некоммерческая образовательная организация высшего образования "Сколковский институт науки и технологий" Способ загрузки неорганических наночастиц или органических молекул в пористые частицы микронного или субмикронного размера
CN111149795A (zh) * 2020-01-14 2020-05-15 成都艾伟孚生物科技有限公司 一种冷冻保护剂及其应用和一种精子冷冻液及其制备方法
CN113440529B (zh) * 2020-03-25 2023-11-14 江苏恒瑞医药股份有限公司 一种可注射的药物组合物及其制备方法
WO2021222545A1 (en) * 2020-04-29 2021-11-04 The Texas A&M University System Naloxone nanoparticle compositions and methods thereof
US20230241051A1 (en) 2020-07-09 2023-08-03 Janssen Pharmaceutica Nv Long-acting formulations
JP2023532982A (ja) 2020-07-09 2023-08-01 ヤンセン ファーマシューティカ エヌ．ベー． 長時間作用型配合物
JP2023532981A (ja) 2020-07-09 2023-08-01 ヤンセン ファーマシューティカ エヌ．ベー． 長時間作用型配合物
WO2022079739A1 (en) 2020-10-14 2022-04-21 Cipla Limited Fixed dose compositions of cabotegravir and rilpivirine
JP6886551B1 (ja) * 2020-11-06 2021-06-16 医療法人祥和会 歯科用の局所麻酔液
CN112641950B (zh) * 2021-01-12 2022-12-16 北京德立福瑞医药科技有限公司 含有难溶性抗肿瘤活性剂的药物组合物及其制备方法
WO2023108156A1 (en) * 2021-12-11 2023-06-15 Beloteca, Inc. Ziprasidone formulations
WO2023154454A1 (en) * 2022-02-10 2023-08-17 Soligenix, Inc. Telmisartan nanosuspension for therapy of respiratory infections and methods of making and using same
TW202406551A (zh) * 2022-04-22 2024-02-16 愛爾蘭商健生科學愛爾蘭無限公司 冷凍乾燥組成物(一)
WO2024068693A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations
WO2024068699A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations
CN116115621A (zh) * 2022-10-31 2023-05-16 广州鹏兴医药科技有限公司 氢氯噻嗪组合物及其制备方法及氢氯噻嗪微针透皮贴剂
CN116919898B (zh) * 2023-09-15 2023-12-19 北京星辉再生科技有限责任公司 米诺地尔纳晶混悬液组合物、米诺地尔纳晶混悬液及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5302401A (en) 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
FR2740686B1 (fr) 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
US20050004049A1 (en) 1997-03-11 2005-01-06 Elan Pharma International Limited Novel griseofulvin compositions
WO2004050068A1 (en) * 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
RU2331424C2 (ru) * 2002-12-13 2008-08-20 Джеготек Аг Топический состав, содержащий наночастицы спиронолактона
JP2006511525A (ja) 2002-12-13 2006-04-06 ヤゴテック アーゲー ナノ粒子状スピロノラクトン局所製剤
CA2605153A1 (en) * 2005-04-13 2006-10-19 Jaymin Chandrakant Shah Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
ES2564241T3 (es) * 2005-12-02 2016-03-21 Glaxosmithkline Biologicals Sa Nanopartículas para su uso en composiciones inmunogénicas
UA97641C2 (en) * 2006-06-23 2012-03-12 Тиботек Фармасьютикелз Лтд. Aqueous suspensions of tmc278
US20100003332A1 (en) * 2006-07-27 2010-01-07 Amorepacific Corporation Process For Preparing Powder Comprising Nanoparticles of Sparingly Soluble Drug
AR065720A1 (es) * 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
DK2175857T3 (da) * 2007-07-12 2013-12-02 Janssen R & D Ireland Krystallinsk form af (e) 4-[[4-[[4-(2-cyanoethenyl)-2.6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitril
US8161810B2 (en) 2008-01-29 2012-04-24 Carefusion 303, Inc. Syringe imaging systems
CN101283982B (zh) * 2008-06-03 2010-06-02 南京工业大学 非诺贝特纳米混悬剂及其制备方法
CN101904820A (zh) * 2009-06-02 2010-12-08 姜玲敏 槲皮素纳米混悬剂冻干组合物及其制备方法和应用
CN101612131B (zh) * 2009-07-17 2011-09-14 郑州大学 2-甲氧基雌二醇纳米混悬剂冻干粉及其制备方法
CN101953808B (zh) * 2010-10-13 2013-03-13 厦门大学 抗肿瘤化合物去乙酰真菌环氧乙酯注射剂及其制备方法

Also Published As

Publication number Publication date
AU2012241726A1 (en) 2013-10-24
AU2012241726C1 (en) 2017-09-14
US20240148726A1 (en) 2024-05-09
RS60651B1 (sr) 2020-09-30
HRP20201241T1 (hr) 2020-11-27
CA2832410A1 (en) 2012-10-18
US20140038996A1 (en) 2014-02-06
BR112013026363A2 (pt) 2016-12-27
MX362344B (es) 2019-01-11
CN103764117A (zh) 2014-04-30
JP2014515021A (ja) 2014-06-26
WO2012140220A1 (en) 2012-10-18
US11389448B2 (en) 2022-07-19
US20220409616A1 (en) 2022-12-29
BR112013026363B1 (pt) 2021-10-13
JP6161593B2 (ja) 2017-07-12
AU2012241726B2 (en) 2017-04-27
LT2696848T (lt) 2020-09-10
CA2832410C (en) 2019-07-23
RU2013150803A (ru) 2015-05-20
ES2823805T3 (es) 2021-05-10
US10166231B2 (en) 2019-01-01
CY1123434T1 (el) 2021-12-31
PL2696848T3 (pl) 2020-12-28
DK2696848T3 (da) 2020-10-12
PT2696848T (pt) 2020-09-03
EP2696848B1 (en) 2020-07-22
RU2643062C2 (ru) 2018-01-30
EP2696848A1 (en) 2014-02-19
HK1257447A1 (zh) 2019-10-18
EP3799860A1 (en) 2021-04-07
SI2696848T1 (sl) 2020-10-30
US11819502B2 (en) 2023-11-21
HUE050970T2 (hu) 2021-01-28
US20160317534A1 (en) 2016-11-03
US20190076428A1 (en) 2019-03-14
CN108210469A (zh) 2018-06-29

Similar Documents

Publication Publication Date Title
MX2013011985A (es) Nanosuspensiones de farmacos secadas por congelamiento.
WO2015061572A8 (en) Inhibitors of the fibroblast growth factor receptor
BR112015011112A2 (pt) composto oligomérico, oligômero, composição farmacêutica, uso do composto oligomérico, método de síntese de um composto oligomérico e método de tratamento de uma doença.
PH12016501122A1 (en) Delayed release compositions of linaclotide
MD4589B1 (ro) Compoziţie farmaceutică cu conţinut de sofosbuvir şi utilizarea acesteia în tratamentul hepatitei virale C
WO2012065022A3 (en) Spiro-oxindole mdm2 antagonists
IL224288A (en) Derivatives of converted pyrazolamide, pharmaceutical preparations containing them and their use
MY162411A (en) Crystalline forms of a macrolide, and uses therefor
ZA201301463B (en) Pharmaceutical compositions for calonolides,their derivatives and analogues,and process for producing the same
GB2499479A (en) Stabilisation of viral particles
WO2011103150A3 (en) Lyophilized preparations of bendamustine
EP3020405A4 (en) Composition for preventing and treating liver fibrosis or liver cirrhosis,containing, as active ingredient, mesenchymal stem cells derived from human embryonic stem cells
WO2012035283A8 (en) Pharmaceutical composition
WO2012162439A3 (en) Compositions comprising fusidic acid and packages therefor
PL3073997T3 (pl) Kompozycja farmaceutyczna zawierająca cząstki środka wiążącego fosforany
WO2012137227A3 (en) Solid forms of antiretroviral compounds and anti-oxidative acids, processes for preparation and pharmaceutical compositions thereof
MX2015005762A (es) Producto de comicronizacion que comprende acetato de ulipristal.
HUP1300647A2 (hu) Ciklosporin A és származékainak komplexei, elõállításuk és gyógyszerészeti kompozícióik
IL226202A0 (en) Methods, compounds and systems for drying@fachem
MX366829B (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
WO2013131644A8 (en) A novel drug delivery system based on jcv-vlp
EP2654725A4 (en) MICROPARTICLE WITH PHYSIOLOGICALLY ACTIVE PEPTIDE, PROCESS FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION THEREWITH
EP2784061A4 (en) ACYLHYDRACO AND OXADIAZOL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE THEREOF
AU333960S (en) Dose disk for dry powder inhaler
EP2569327A4 (en) EIF4E BINDING PEPTIDES

Legal Events

Date Code Title Description
FG Grant or registration